AU2006228949A1 - Compositions for oral transmucosal delivery of metformin - Google Patents

Compositions for oral transmucosal delivery of metformin Download PDF

Info

Publication number
AU2006228949A1
AU2006228949A1 AU2006228949A AU2006228949A AU2006228949A1 AU 2006228949 A1 AU2006228949 A1 AU 2006228949A1 AU 2006228949 A AU2006228949 A AU 2006228949A AU 2006228949 A AU2006228949 A AU 2006228949A AU 2006228949 A1 AU2006228949 A1 AU 2006228949A1
Authority
AU
Australia
Prior art keywords
composition
subject
metformin
concentration
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006228949A
Other languages
English (en)
Inventor
Anna E. Gluskin
Muhammad Waseem Tahir Qazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
GENEREX PHARM Inc
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENEREX PHARM Inc, Generex Pharmaceuticals Inc filed Critical GENEREX PHARM Inc
Publication of AU2006228949A1 publication Critical patent/AU2006228949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006228949A 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin Abandoned AU2006228949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30
US60/666,475 2005-03-30
PCT/CA2006/000472 WO2006102752A1 (en) 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin

Publications (1)

Publication Number Publication Date
AU2006228949A1 true AU2006228949A1 (en) 2006-10-05

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006228949A Abandoned AU2006228949A1 (en) 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin

Country Status (16)

Country Link
US (1) US20090069437A1 (enExample)
EP (1) EP1863465A4 (enExample)
JP (1) JP2008534523A (enExample)
AR (1) AR052960A1 (enExample)
AU (1) AU2006228949A1 (enExample)
BR (1) BRPI0611555A2 (enExample)
CA (1) CA2603450A1 (enExample)
CR (1) CR9363A (enExample)
IL (1) IL185931A0 (enExample)
MX (1) MX2007012047A (enExample)
NZ (1) NZ560990A (enExample)
PE (1) PE20061245A1 (enExample)
RU (2) RU2409357C2 (enExample)
UY (1) UY29445A1 (enExample)
WO (1) WO2006102752A1 (enExample)
ZA (1) ZA200708834B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
CA2710815A1 (en) * 2008-01-16 2009-07-23 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
WO2010149170A1 (en) * 2009-06-24 2010-12-29 Københavns Universitet Treatment of insulin resistance and obesity by stimulating glp-1 release
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
US12303479B2 (en) * 2019-05-06 2025-05-20 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
ES2224634T3 (es) * 1998-04-29 2005-03-01 Sumitomo Pharmaceuticals Company, Limited Formulacion oral que comprende biguanida y un acido organico.
DE69818444T2 (de) * 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
JP2004531463A (ja) * 2000-11-03 2004-10-14 アンドルクス ラブス，エルエルシー 徐放メトホルミン組成物
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
RU2006118801A (ru) * 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина

Also Published As

Publication number Publication date
RU2409357C2 (ru) 2011-01-20
JP2008534523A (ja) 2008-08-28
EP1863465A4 (en) 2010-12-15
WO2006102752A1 (en) 2006-10-05
ZA200708834B (en) 2008-11-26
CA2603450A1 (en) 2006-10-05
MX2007012047A (es) 2007-12-12
US20090069437A1 (en) 2009-03-12
PE20061245A1 (es) 2007-01-06
NZ560990A (en) 2009-02-28
EP1863465A1 (en) 2007-12-12
CR9363A (es) 2008-02-12
RU2010139163A (ru) 2012-03-27
IL185931A0 (en) 2008-02-09
RU2007139886A (ru) 2009-05-10
AR052960A1 (es) 2007-04-11
UY29445A1 (es) 2006-10-02
BRPI0611555A2 (pt) 2010-09-21

Similar Documents

Publication Publication Date Title
JP5179757B2 (ja) 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US6375982B1 (en) Rapid-melt semi-solid compositions, methods of making same and method of using same
US20120058962A1 (en) Buccal and/or sublingual therapeutic formulation
CA2461517C (en) Nicotine formulations comprising cocoa and use thereof
WO2009080023A1 (en) Compressed chewing gum comprising peptide
SG174785A1 (en) Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20090069437A1 (en) Compositions for Oral Transmucosal Delivery of Metformin
US12589135B2 (en) Topical administration of GLP-1 receptor agonists
CN115887379A (zh) 一种维生素d3喷雾剂及其制备方法
US20100249178A1 (en) Compositions and methods for treating middle-of-the-night insomnia
CA2743615A1 (en) Compositions and methods for alleviating hyposalivation and for providing oral comfort
JPH05501854A (ja) 親油性薬剤の非侵襲性用量対効果式投与のための方法及び組成物
US20190099368A1 (en) Chewable dosage forms containing sitagliptin and metformin
US20160361257A1 (en) Composition for increasing testosterone levels and enhancing libido
RU2389493C2 (ru) Композиция и способ для повышения уровня глюкозы в крови
J Tangso et al. Confectionery-based dose forms
US11096890B2 (en) Chewable dosage forms containing sitagliptin and metformin
MXPA06009296A (es) Composiciones para suministro de agentes hipnoticos a traves de la mucosa oral y sus metodos de uso.
Lakkis Encapsulation and controlled release applications in confectionery and oral care products
US20080085331A1 (en) Composition and method for raising blood glucose level
Ughade et al. Medicated chewing gum: Modern approach to mucosal drug delivery
EP1054674B1 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
CA2562821A1 (en) Composition and method for raising blood glucose level
JP2002121146A (ja) 歯周病予防用製剤
AU2009313865B2 (en) Compositions and methods for alleviating hyposalivation and for providing oral comfort

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application